Fig. 3

LINC02159 targeted miR-1285-3p in TNBC. (A) The putative binding between LINC02159 with miR-1285-3p. (B) TNBC cells were transfected with miR-NC or miR-1285-3p and wild-type or mutated sequence of LINC02159. The predictive binding of LINC02159 and miR-1285-3p was validated via the luciferase reporter assay. (C) TNBC cells were transfected with control-vector or LINC02159, and the expression level of miR-1285-3p was determined by RT-qPCR analysis. (D) LINC02159 was depleted by transfecting siRNA oligos, and miR-1285-3p levels were detected. (E) miR-1285-3p expression in TNBC tissues and non-cancerous tissues was compared and lower miR-1285-3p levels were found in TNBC tissues. The experiment was performed with 50 biological replicates (n = 50). (F) miR-1285-3p was lowerly expressed in TNBC cell lines in comparison to that of the normal cell MCF10A. (G) RNA immunoprecipitation assay was carried out to validate the binding between miR-1285-3p and LINC02159. Both miR-1285-3p and LINC02159 were found in the immunoprecipitants of Ago2 antibody. The experiment in (B,C,D,F,G) was performed with 3 biological replicates.